Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Edulis Therapeutics
AddedFeb 17, 2024
UpdatedJun 18, 2026
Edulis Therapeutics

Edulis Therapeutics

Angel

Carnegie Mellon spinout developing a sustained drug-delivery platform for chronic GI diseases.

HQ
Pittsburgh, PA, US
Founded
2022
Overview
Compare
Fundraising
Employees
Website

Edulis Therapeutics, a Carnegie Mellon spinout, is dedicated to revolutionizing gastrointestinal medicine through its innovative drug-delivery platform. The company focuses on chronic gastrointestinal diseases, offering a sustained, maintenance-free medication system. Their endoscopic drug delivery implant, thinner than a grain of rice, uses a bioresorbable polymer matrix to deliver medicine precisely and safely.

Edulis Therapeutics has made significant strides in improving patient care, impacting millions with its long-term management solutions. The implant can last for several months, providing a consistent and controlled release of medication. This breakthrough technology enhances the quality of life for patients by reducing the need for frequent treatments.

Edulis Therapeutics - Similar Companies

Intact Therapeutics logo

Intact Therapeutics

Enable Therapeutics logo

Enable Therapeutics

Mechano-Therapeutics logo

Mechano-Therapeutics

Syntis Bio logo

Syntis Bio

syntis.bio

Endosphere logo

Endosphere

Eugit Therapeutics logo

Eugit Therapeutics

eugittx.com

Cytonus Therapeutics logo

Cytonus Therapeutics

cytonus.com

InSitu Biologics logo

InSitu Biologics

Mati Therapeutics logo

Mati Therapeutics

BioSapien logo

BioSapien

biosapien.com

Edimer Pharmaceuticals logo

Edimer Pharmaceuticals

Extend Biosciences logo

Extend Biosciences

extendbio.com

Controlled Delivery Systems logo

Controlled Delivery Systems

Zenomics logo

Zenomics

Talima Therapeutics logo

Talima Therapeutics

talima.com

Edulis Therapeutics - Quick Facts

Who are Edulis Therapeutics' competitors?

Companies similar to Edulis Therapeutics include Intact Therapeutics, Enable Therapeutics, Mechano-Therapeutics and Syntis Bio.

When was Edulis Therapeutics founded?

Edulis Therapeutics was founded in 2022.

Where is Edulis Therapeutics' headquarters located?

Edulis Therapeutics' headquarters is located in Pittsburgh, PA, US.

When was Edulis Therapeutics' last funding round?

Edulis Therapeutics' most recent funding round was for $15k (USD) in March 2023.

How much has Edulis Therapeutics raised to-date?

As of Mar 21, 2023, Edulis Therapeutics has raised a total of $15k (USD).

How many employees does Edulis Therapeutics have?

Edulis Therapeutics has 2 employees as of Feb 4, 2024.

Edulis Therapeutics - Classification

Industry
  • Hardware
Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Main Product
  • Drug Delivery
Tags
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 8 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research